Outcomes in randomized RO– LCH-III patients*
| RO– Trial: Patients w/o RO involvement . | Arm C . | Arm D . | P value . |
|---|---|---|---|
| (RO–) | 6 mo | 12 mo | |
| Randomized patients (n) | 98 | 89 | |
| Reactivations/worsening after month 6 primary end point | |||
| Reactivations/patients | 41/86 | 28/82 | |
| 3-y cumulative incidence % ± SE | 44 ± 6 | 34 ± 5 | .03 |
| 5-y cumulative incidence % ± SE | 54 ± 6 | 37 ± 6 | |
| Survival | |||
| Deaths/patients | 1/94 | 1/85 | |
| 3-y = 5-y pSU % ± SE | 100 | 99 ± 1 | .96 |
| Diabetes insipidus | |||
| At Dx/pts. | 16/94 | 15/85 | |
| Developed DI/eval. pts | 9/78 | 8/70 | .83 |
| 3-y cumulative incidence % ± SE | 12 ± 4 | 12 ± 4 |
| RO– Trial: Patients w/o RO involvement . | Arm C . | Arm D . | P value . |
|---|---|---|---|
| (RO–) | 6 mo | 12 mo | |
| Randomized patients (n) | 98 | 89 | |
| Reactivations/worsening after month 6 primary end point | |||
| Reactivations/patients | 41/86 | 28/82 | |
| 3-y cumulative incidence % ± SE | 44 ± 6 | 34 ± 5 | .03 |
| 5-y cumulative incidence % ± SE | 54 ± 6 | 37 ± 6 | |
| Survival | |||
| Deaths/patients | 1/94 | 1/85 | |
| 3-y = 5-y pSU % ± SE | 100 | 99 ± 1 | .96 |
| Diabetes insipidus | |||
| At Dx/pts. | 16/94 | 15/85 | |
| Developed DI/eval. pts | 9/78 | 8/70 | .83 |
| 3-y cumulative incidence % ± SE | 12 ± 4 | 12 ± 4 |
Differences in total patient numbers in the response data (vs total number of randomized patients) reflect exclusions for missing information or follow-up.